
- /
- Supported exchanges
- / NASDAQ
Veracyte Inc (VCYT NASDAQ) stock market data APIs
Veracyte Inc Financial Data Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Veracyte Inc data using free add-ons & libraries
Get Veracyte Inc Fundamental Data
Veracyte Inc Fundamental data includes:
- Net Revenue: 425 M
- EBITDA: 44 014 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-06
- EPS/Forecast: 0.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Veracyte Inc News

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
Findings Further Expand Company’s Extensive Clinical Evidence In Urologic Cancers SOUTH SAN FRANCISCO, Calif., February 05, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer di...


Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
SOUTH SAN FRANCISCO, Calif., February 04, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fou...

Brian's Big Idea: Healthcare Stocks
One of the most difficult sectors to invest in is the healthcare sector. Not only do you have to be nuanced in the ways of the stock market but you also have to have a deep understanding of medicines,...

3 US Stocks Estimated To Be Undervalued By Up To 49.9% Presenting An Opportunity
As U.S. stock futures point to a lower open amid concerns about Chinese advances in artificial intelligence, the market is experiencing heightened volatility, particularly within the tech sector. In s...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.